Similar articles for PMID: 17425547

Year	Number of Results
1988	1
1994	2
1995	1
1996	1
1997	1
1999	2
2001	5
2002	3
2003	5
2004	6
2005	7
2006	5
2007	4
2008	3
2009	7
2010	5
2011	6
2012	10
2013	10
2014	7
2015	4
2016	3
2017	4
2018	1
2019	3
2020	4
2021	1

1

Clinical predictors of treatment failure for diabetic foot infections: data from a prospective trial.

Lipsky BA, Sheehan P, Armstrong DG, Tice AD, Polis AB, Abramson MA. Lipsky BA, et al. Int Wound J. 2007 Mar;4(1):30-8. doi: 10.1111/j.1742-481X.2006.00274.x. Int Wound J. 2007. PMID: 17425547

2

Ertapenem versus piperacillin/tazobactam for diabetic foot infections (SIDESTEP): prospective, randomised, controlled, double-blinded, multicentre trial.

Lipsky BA, Armstrong DG, Citron DM, Tice AD, Morgenstern DE, Abramson MA. Lipsky BA, et al. Lancet. 2005 Nov 12;366(9498):1695-703. doi: 10.1016/S0140-6736(05)67694-5. Lancet. 2005. PMID: 16291062 Clinical Trial.

3

Treating diabetic foot infections with sequential intravenous to oral moxifloxacin compared with piperacillin-tazobactam/amoxicillin-clavulanate.

Lipsky BA, Giordano P, Choudhri S, Song J. Lipsky BA, et al. J Antimicrob Chemother. 2007 Aug;60(2):370-6. doi: 10.1093/jac/dkm130. Epub 2007 Jun 6. J Antimicrob Chemother. 2007. PMID: 17553812 Clinical Trial.

4

An open-label, randomized study comparing efficacy and safety of intravenous piperacillin/tazobactam and ampicillin/sulbactam for infected diabetic foot ulcers.

Harkless L, Boghossian J, Pollak R, Caputo W, Dana A, Gray S, Wu D. Harkless L, et al. Surg Infect (Larchmt). 2005 Spring;6(1):27-40. doi: 10.1089/sur.2005.6.27. Surg Infect (Larchmt). 2005. PMID: 15865549 Clinical Trial.

5

Comparative costs of ertapenem and piperacillin-tazobactam in the treatment of diabetic foot infections.

Tice AD, Turpin RS, Hoey CT, Lipsky BA, Wu J, Abramson MA. Tice AD, et al. Am J Health Syst Pharm. 2007 May 15;64(10):1080-6. doi: 10.1093/ajhp/64.10.1080. Am J Health Syst Pharm. 2007. PMID: 17494908

6

Piperacillin/tazobactam versus imipenem/cilastatin for severe diabetic foot infections: a prospective, randomized clinical trial in a university hospital.

Saltoglu N, Dalkiran A, Tetiker T, Bayram H, Tasova Y, Dalay C, Sert M. Saltoglu N, et al. Clin Microbiol Infect. 2010 Aug;16(8):1252-7. doi: 10.1111/j.1469-0691.2009.03067.x. Epub 2009 Oct 14. Clin Microbiol Infect. 2010. PMID: 19832720 Free article. Clinical Trial.

7

Correlation of adherence to the 2012 Infectious Diseases Society of America practice guidelines with patient outcomes in the treatment of diabetic foot infections in an outpatient parenteral antimicrobial programme.

Pence LM, Mock CM, Kays MB, Damer KM, Muloma EW, Erdman SM. Pence LM, et al. Diabet Med. 2014 Sep;31(9):1114-20. doi: 10.1111/dme.12501. Epub 2014 Jun 16. Diabet Med. 2014. PMID: 24825001

8

Ertapenem versus piperacillin/tazobactam for the treatment of complicated infections: a meta-analysis of randomized controlled trials.

An MM, Zou Z, Shen H, Zhang JD, Chen ML, Liu P, Wang R, Jiang YY. An MM, et al. BMC Infect Dis. 2009 Dec 2;9:193. doi: 10.1186/1471-2334-9-193. BMC Infect Dis. 2009. PMID: 19951447 Free PMC article.

9

Post-treatment leukocytosis predicts an unfavorable clinical response in patients with moderate to severe diabetic foot infections.

Fleischer AE, Wrobel JS, Leonards A, Berg S, Evans DP, Baron RL, Armstrong DG. Fleischer AE, et al. J Foot Ankle Surg. 2011 Sep-Oct;50(5):541-6. doi: 10.1053/j.jfas.2011.04.023. Epub 2011 May 31. J Foot Ankle Surg. 2011. PMID: 21621432

10

Treatment of polymicrobial infections: post hoc analysis of three trials comparing ertapenem and piperacillin-tazobactam.

Solomkin J, Teppler H, Graham DR, Gesser RM, Meibohm AR, Roy S, Woods GL. Solomkin J, et al. J Antimicrob Chemother. 2004 Jun;53 Suppl 2:ii51-7. doi: 10.1093/jac/dkh206. J Antimicrob Chemother. 2004. PMID: 15150183 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed